^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    15h
    Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study (clinicaltrials.gov)
    P2, N=37, Recruiting, Ningbo Medical Center Lihuili Hospital
    New P2 trial • IO biomarker
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab)
    17h
    DISTINKT: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, ImmuneOncia Therapeutics Inc. | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    20h
    AMBITION: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P3, N=281, Completed, Japanese Foundation for Cancer Research | Trial completion date: Sep 2025 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    21h
    ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)
    P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    22h
    Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (clinicaltrials.gov)
    P2, N=6, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Nov 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab)
    22h
    Durvalumab and Tremelimumab for Pediatric Malignancies (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    23h
    BEATcc: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (clinicaltrials.gov)
    P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel
    1d
    Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Huashan Hospital
    New P1 trial
    |
    Tecentriq (atezolizumab) • YSCH-01
    1d
    SHR-A1811-II-203: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=324, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Nov 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    2d
    Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, The Methodist Hospital Research Institute | N=39 --> 51 | Trial completion date: Dec 2025 --> Dec 2028
    Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • PD-L1 negative
    |
    BluePrint
    |
    Herceptin (trastuzumab) • Imfinzi (durvalumab) • Perjeta (pertuzumab)
    2d
    Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Feb 2026 --> Feb 2027 | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)
    3d
    Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) (2024-513219-29-00)
    P2/3, N=203, Recruiting, University College London | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)